CoChat

Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder

Davidson, Jonathan, Yaryura-Tobias, Jose, DuPont, Robert, Stallings, Loretta, Barbato, Luigi M., van der Hoop, Roland Gerritsen, Li, David · 2004 · Journal of Clinical Psychopharmacology
Cited by 69

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Generalized social anxiety disorder is a highly prevalent anxiety disorder with deleterious effects on social and family relationships, as well as work performance. We report the results of a multicenter, randomized, placebo-controlled trial comparing the efficacy, safety, and tolerability of fluvoxamine controlled release (CR) to placebo in patients with generalized social anxiety disorder. METHODS: A total of 279 adult patients meeting all inclusion/exclusion criteria was recruited at 23 United States sites and randomly assigned to receive either fluvoxamine CR (100-300 mg/d) or placebo for 12 weeks. The dose could be increased, based on efficacy and tolerability, in increments of 50 mg/d at weekly intervals. The dosage remained constant during weeks 6 to 12. RESULTS: Treatment with fluvoxamine CR resulted in statistically and clinically significant improvements in symptoms associated with generalized social anxiety disorder as early as week 4 on the Liebowitz Social Anxiety Scale and the Clinical Global Impression Scale Global Improvement, and at week 6 on the Sheehan Disability Scale, Clinical Global Impression Scale Severity of Illness and the Patient Global Impression of Improvement Scale. The most frequent adverse events reported by patients on fluvoxamine CR were headache, nausea, somnolence, and insomnia. No weight gain was observed for either treatment group, and at end point, there were no differences between treatments on overall sexual function, as measured by the Arizona Sexual Experience Scale. CONCLUSIONS: Both physician and patient-rated scales indicate that fluvoxamine CR is effective and safe for the treatment of generalized social anxiety disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000106222.36344.96

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 24

  1. Judd, 1994, Social phobia: a clinical overview., J Clin Psychiatry, 55, 5
  2. Donohue, 1994, Behavioral assessment and treatment of social phobia., Behav Modif, 18, 262, 10.1177/01454455940183002 · DOI
  3. Den Boer, 1997, Social phobia: epidemiology, recognition and treatment., BMJ, 315, 796, 10.1136/bmj.315.7111.796 · DOI · Paper page
  4. Schneier, 1994, Functional impairment in social phobia., J Clin Psychiatry, 55, 8
  5. Davidson, 1993, The epidemiology of social phobia: findings from the duke epidemiological catchment area study., Psychol Med, 23, 709, 10.1017/S0033291700025484 · DOI · Paper page
  6. Liebowitz, 1985, Social phobia: review of a neglected anxiety disorder., Arch Gen Psychiatry, 42, 729, 10.1001/archpsyc.1985.01790300097013 · DOI · Paper page
  7. Kessler, 1994, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey., Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  8. Versiani, 1992, Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine., Br J Psychiatry, 161, 353, 10.1192/bjp.161.3.353 · DOI · Paper page
  9. Davidson, 1993, Treatment of social phobia with clonazepam and placebo., J Clin Psychopharmacol, 13, 423, 10.1097/00004714-199312000-00008 · DOI · Paper page
  10. Pande, 1999, Treatment of social phobia with gabapentin: a placebo-controlled study., J Clin Psychopharmacol, 19, 341, 10.1097/00004714-199908000-00010 · DOI · Paper page
  11. Baldwin, 1999, Paroxetine in social phobia/social anxiety disorder. Randomized, double-blind, placebo-controlled study., Br J Psychiatry, 175, 120, 10.1192/bjp.175.2.120 · DOI · Paper page
  12. Stein, 1998, Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial., JAMA, 280, 708, 10.1001/jama.280.8.708 · DOI · Paper page
  13. Van Vliet, 1994, Psychopharmacological treatment of social phobia; a double-blind placebo controlled study with fluvoxamine., Psychopharmacology (Berl), 115, 128, 10.1007/BF02244762 · DOI · Paper page
  14. Stein, 1999, Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study., Am J Psychiatry, 156, 756, 10.1176/ajp.156.5.756 · DOI · Paper page
  15. Van Ameringen, 2001, Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study., Am J Psychiatry, 158, 2, 10.1176/appi.ajp.158.2.275 · DOI · Paper page
  16. Katzelnick, 1995, Sertraline for social phobia: a double-blind, placebo-controlled crossover study., Am J Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
  17. Kobak, 2002, Fluoxetine in social phobia: a double-blind, placebo-controlled study., J Clin Psychopharmacol, 22, 257, 10.1097/00004714-200206000-00005 · DOI · Paper page
  18. Nemeroff, 1995, Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients., Depress, 3, 163, 10.1002/depr.3050030402 · DOI · Paper page
  19. Waldinger, 1998, Effect of SSRI Antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline., J Clin Psychopharmacol, 18, 274, 10.1097/00004714-199808000-00004 · DOI · Paper page
  20. McGahuey, 2000, The Arizona Sexual Experience Scale (ASEX): reliability and validity., J Sex and Marital Ther, 26, 25, 10.1080/009262300278623 · DOI · Paper page
  21. Montgomery, 1979, A new depression scale designed to be sensitive to change., B J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  22. Fava, 2000, Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment., J Clin Psychiatry, 61, 863, 10.4088/JCP.v61n1109 · DOI · Paper page
  23. Bitran, 1987, Pharmacological analysis of male rat sexual behavior., Neurosci Biobehav Rev, 11, 365, 10.1016/S0149-7634(87)80008-8 · DOI · Paper page
  24. Oliver, 1999, Stimulus properties of the selective 5-HT reuptake inhibitor fluvoxamine in conditioned taste aversion procedures., Pharmacol Biochem Behav, 64, 213, 10.1016/S0091-3057(99)00082-9 · doi:10.1016/s0091-3057(99)00082-9

Cited by

See all 69

Metadata

Authors
Davidson, J., Yaryura-Tobias, J., DuPont, R., Stallings, L., Barbato, L. M., van der Hoop, R. G., & Li, D.
Venue
Journal of Clinical Psychopharmacology
Published
2004-04
Volume
24
Issue
2
Pages
118-125
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1969610924
Cited by
69
References
4
FWCI
5.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder. https://app.cochat.ai/papers/10.1097/01.jcp.0000106222.36344.96
The paper
Davidson, J., Yaryura-Tobias, J., DuPont, R., Stallings, L., Barbato, L. M., van der Hoop, R. G., & Li, D. (2004). Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000106222.36344.96

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.